Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2023

Activité de la polyarthrite rhumatoïde et effets indésirables chez les patients recevant du tofacitinib ou des inhibiteurs du facteur de nécrose tumorale : Une analyse post hoc de ORAL Surveillance

Ther Adv Musculoskelet Dis. 2023;15:1759720X231201047 doi: 10.1177/1759720X231201047

Wang C,

Chen Y,

Menon S,

Connell CA,

Ytterberg SR,

Mortezavi M

Post hoc analysis of ORAL Surveillance data highlights that active disease in RA leads to higher risk of adverse medical events, regardless of medication used.

Keywords:

Outcomes

March 2023

Malignancy Risk with Tofacitinib versus TNF Inhibitors in Rheumatoid Arthritis: Results from the Open-Label, Randomised Controlled Oral Surveillance Trial

Ann Rheum Dis. 2023;82(3):331–343 doi: 10.1136/ard-2022-222543

Chen YH,

Wang C,

Wu J,

Menon S,

Vranic I,

Gómez-Reino JJ

Results from the open-label, randomised controlled ORAL Surveillance trial find increased risk of malignancies with tofacitinib versus TNFi, highlighting the highest incidence in patients with a history of atherosclerotic cardiovascular disease or increasing cardiovascular risk.

Keywords:

February 2023

Impact de l'enrichissement du risque cardiovasculaire sur l'incidence des effets cardiovasculaires indésirables majeurs dans le cadre du programme clinique tofacitinib dans la polyarthrite rhumatoïde

Ann Rheum Dis. 2023;82(4):575–577 doi: 10.1136/ard-2022-223406

Koch GG,

Wu J,

Wang C,

Kwok K,

Menon S,

Data suggest that an important difference between P123LTE and ORAL Surveillance was the proportion of patients with a history of atherosclerotic CV disease (ASCVD).